Lyell Immunopharma, Inc. (LYEL)
NASDAQ · Healthcare
Lyell Immunopharma, Inc. EBITDA 2019–2025
Lyell Immunopharma, Inc. annual/quarterly ebitda history and growth rate from 2019 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Lyell Immunopharma, Inc. ebitda for the quarter ending March 31, 2026 was -41.9 M, a 22.25% decrease year-over-year.
- Lyell Immunopharma, Inc. ebitda for the twelve months ending March 31, 2026 was -203.9 M.
- Lyell Immunopharma, Inc. annual ebitda for 2025 was -257.9 M, a 23.96% decrease from 2024.
- Lyell Immunopharma, Inc. annual ebitda for 2024 was -339.1 M, a 49.55% increase from 2023.
- Lyell Immunopharma, Inc. annual ebitda for 2023 was -226.8 M, a 34.15% increase from 2022.
- Lyell Immunopharma, Inc. annual ebitda for 2022 was -169.0 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Lyell Immunopharma, Inc. EBITDA — FAQ
Lyell Immunopharma, Inc. (LYEL) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LYEL's ebitda history?
The chart and table above show Lyell Immunopharma, Inc.'s ebitda by year and by quarter, including the growth rate.